No abstract available.
Chemotherapy, Adjuvant ; Colorectal Neoplasms ; Humans

PURPOSE: The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection. MATERIALS AND METHODS: Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors. RESULTS: In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups. CONCLUSION: The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.
Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Gallbladder Neoplasms* ; Gallbladder* ; Humans ; Propensity Score

PURPOSE: Dukes' A & B colorectal cancer patients are often excluded from adjuvant chemotherapy following potentially curative surgery because they are expected to have good long-term survival. However, actually 20 ~ 30% of these patients suffer from recurrent disease, so it would be helpful for these patients of recurrent disease to be able to select a high risk group. METHODS: In 78 Dukes' A & B colorectal cancers, we investigated by immunohistochemistry the role of molecular markers, such as p27(kip1), p53, Ki-67, and Skp2, in identifying high-risk patients. RESULTS: Patients with low p27(kip1) expression showed poor overall survival compared to those with high p27(kip1) expressions (55.3 versus 66.7 months, P=0.018). The only significant factor associated with p27(kip1) expression was p53 expression. The low p27(kip1) expression and positive p53 expression group had poor overall survival (54.3 months, P=0.036). CONCLISIONS: In a node-negative colorectal carcinoma, the molecular marker p27(kip1) does not play an independent prognostic role, but it may have prognostic significance in correlation with other markers such as p53, Ki-67, and Skp2. The assessment of molecular alterations may be useful to node-negative colorectal patients in identifying the high risk group that may benefit from adjuvant chemotherapy.
Chemotherapy, Adjuvant ; Colorectal Neoplasms ; Humans ; Immunohistochemistry ; Prognosis

Malignant mesothelioma is a rare neoplasm and arises from the serosal lining of the pleural, peritoneal and pericardial cavities. The median survival rang from 5 to 12 months, mainly because of lack of effective treatment. The incidence is approximately one per 1,000,000 and peritoneal mesothelioma represents one fourth of all mesotheliomas. There is a relationship between mesothelioma and asbestos exposure, but non-asbestos related cases were reported. Treatments of malignant mesothelioma are cytoreductive surgery and adjuvant chemotherapy, but current treatment options are unsatisfactory. We report two cases of malignant mesothelioma of the peritoneum and pericardium treated by operation and adjuvant chemotherapy with a brief review of literature.
Asbestos ; Chemotherapy, Adjuvant ; Incidence ; Mesothelioma ; Pericardium ; Peritoneum

Malignant mesothelioma of the uterus is a rare mesenchymal neoplasm originating from the mesothelial surface cell lining of the uterus. It is known to have very poor prognosis with median survival period of 4-18 months. We report a rare case of primary malignant mesothelioma of the uterus showing no evidence of recurrence for 2 years, after management with operation and adjuvant chemotherapy.
Chemotherapy, Adjuvant ; Mesothelioma* ; Peritoneum ; Prognosis ; Recurrence ; Uterus*

No abstract available.
Chemoradiotherapy* ; Chemotherapy, Adjuvant* ; Humans ; Nasopharyngeal Neoplasms*

No abstract available.
Chemotherapy, Adjuvant* ; Colonic Neoplasms* ; Humans ; Prognosis*

Desmoplastic cerebral astrocytoma of infancy is a rare neoplasm with distinctive clinical and radiographicfeatures. Almost all cases present in the first two years of life as a large, supratentorial, enhancing mass witha peripheral dural-based solid component and a central cystic component. After complete surgical excision, thecourse of this tumor is benign, and adjuvant chemotherapy or radiation therapy may not be required. We describethe case of a 9-month-old boy with a desmoplastic cerebral astrocytoma of infancy and review the associatedliterature.
Astrocytoma ; Chemotherapy, Adjuvant ; Humans ; Infant ; Male

Desmoplastic cerebral astrocytoma of infancy is a rare neoplasm with distinctive clinical and radiographicfeatures. Almost all cases present in the first two years of life as a large, supratentorial, enhancing mass witha peripheral dural-based solid component and a central cystic component. After complete surgical excision, thecourse of this tumor is benign, and adjuvant chemotherapy or radiation therapy may not be required. We describethe case of a 9-month-old boy with a desmoplastic cerebral astrocytoma of infancy and review the associatedliterature.
Astrocytoma ; Chemotherapy, Adjuvant ; Humans ; Infant ; Male

Desmoplastic cerebral astrocytoma of infancy is a rare neoplasm with distinctive clinical and radiographicfeatures. Almost all cases present in the first two years of life as a large, supratentorial, enhancing mass witha peripheral dural-based solid component and a central cystic component. After complete surgical excision, thecourse of this tumor is benign, and adjuvant chemotherapy or radiation therapy may not be required. We describethe case of a 9-month-old boy with a desmoplastic cerebral astrocytoma of infancy and review the associatedliterature.
Astrocytoma ; Chemotherapy, Adjuvant ; Humans ; Infant ; Male